We measured cardiac performance sequentially, using quantitative radionuclide angiocardiography to estimate left ventricular ejection fraction in 55 patients receiving doxorubicin for treatment of cancer. With final doxorubicin dosages greater than 350 mg per square meter, the lowest ejection fraction measured was significantly less than the initial determination. Five patients had severe cardiotoxicity (congestive heart failure). All had an ejection fraction of less than 30 per cent at the time of heart failure, and demonstrated moderate cardiotoxicity (a decline in ejection fraction by at least 15 per cent to a final value of less than 45 per cent) before clinical manifestations. Six patients with moderate toxicity in whom doxorubicin was discontinued did not have heart failure or a further decline in ejection fraction during the follow-up period. Moderate toxicity was continued, but mild toxicity (decline of ejection fraction by greater than 10 per cent, noted in 11 patients) was not well predicted. The assessment of radionuclide left ventricular ejection fraction during doxorubicin therapy may make it possible to avoid congestive heart failure.
This article has been cited by other articles:
Moss, R. W.
(2006). Should patients undergoing chemotherapy and radiotherapy be prescribed antioxidants?. Integr Cancer Ther
5: 63-82
[Abstract]
Floyd, J. D., Nguyen, D. T., Lobins, R. L., Bashir, Q., Doll, D. C., Perry, M. C.
(2005). Cardiotoxicity of Cancer Therapy. JCO
23: 7685-7696
[Abstract][Full Text]
Sandri, M. T., Salvatici, M., Cardinale, D., Zorzino, L., Passerini, R., Lentati, P., Leon, M., Civelli, M., Martinelli, G., Cipolla, C. M.
(2005). N-Terminal Pro-B-Type Natriuretic Peptide after High-Dose Chemotherapy: A Marker Predictive of Cardiac Dysfunction?. Clin. Chem.
51: 1405-1410
[Abstract][Full Text]
Bonneterre, J., Roche, H., Kerbrat, P., Fumoleau, P., Goudier, M.-J., Fargeot, P., Montcuquet, P., Clavere, P., Barats, J.-C., Monnier, A., Veyret, C., Datchary, J., Van Praagh, I., Chapelle-Marcillac, I.
(2004). Long-Term Cardiac Follow-Up in Relapse-Free Patients After Six Courses of Fluorouracil, Epirubicin, and Cyclophosphamide, With Either 50 or 100 mg of Epirubicin, As Adjuvant Therapy for Node-Positive Breast Cancer: French Adjuvant Study Group. JCO
22: 3070-3079
[Abstract][Full Text]
Cardinale, D., Sandri, M. T., Colombo, A., Colombo, N., Boeri, M., Lamantia, G., Civelli, M., Peccatori, F., Martinelli, G., Fiorentini, C., Cipolla, C. M.
(2004). Prognostic Value of Troponin I in Cardiac Risk Stratification of Cancer Patients Undergoing High-Dose Chemotherapy. Circulation
109: 2749-2754
[Abstract][Full Text]
Bountioukos, M, Doorduijn, J.K., Roelandt, J.R.T.C., Vourvouri, E.C., Bax, J.J., Schinkel, A.F.L., Kertai, M.D., Sonneveld, P., Poldermans, D.
(2003). Repetitive Dobutamine Stress Echocardiography for the Prediction of Anthracycline Cardiotoxicity. Eur J Echocardiogr
4: 300-305
[Abstract][Full Text]
Tallarico, D., Rizzo, V., di Maio, F., Petretto, F., Bianco, G., Placanica, G., Marziali, M., Paravati, V., Gueli, N., Meloni, F., Campbell, S. V.
(2003). Myocardial Cytoprotection by Trimetazidine Against Anthracycline-Induced Cardiotoxicity in Anticancer Chemotherapy. ANGIOLOGY
54: 219-227
[Abstract]
Limat, S., Demesmay, K., Voillat, L., Bernard, Y., Deconinck, E., Brion, A., Sabbah, A., Woronoff-Lemsi, M. C., Cahn, J. Y.
(2003). Early cardiotoxicity of the CHOP regimen in aggressive non-Hodgkin's lymphoma. Ann Oncol
14: 277-281
[Abstract][Full Text]
Goethals, I., De Winter, O., De Bondt, P., De Sutter, J., Dierckx, R., Van De Wiele, C.
(2002). The clinical value of nuclear medicine in the assessment of irradiation-induced and anthracycline-associated cardiac damage. Ann Oncol
13: 1331-1339
[Abstract][Full Text]
Batist, G., Ramakrishnan, G., Rao, C. S., Chandrasekharan, A., Gutheil, J., Guthrie, T., Shah, P., Khojasteh, A., Nair, M. K., Hoelzer, K., Tkaczuk, K., Park, Y. C., Lee, L. W.
(2001). Reduced Cardiotoxicity and Preserved Antitumor Efficacy of Liposome-Encapsulated Doxorubicin and Cyclophosphamide Compared With Conventional Doxorubicin and Cyclophosphamide in a Randomized, Multicenter Trial of Metastatic Breast Cancer. JCO
19: 1444-1454
[Abstract][Full Text]
Granda, T. G., Filipski, E., D’Attino, R. M., Vrignaud, P., Anjo, A., Bissery, M. C., Lévi, F.
(2001). Experimental Chronotherapy of Mouse Mammary Adenocarcinoma MA13/C with Docetaxel and Doxorubicin as Single Agents and in Combination. Cancer Res.
61: 1996-2001
[Abstract][Full Text]
Nabholtz, J. M., Mackey, J. R., Smylie, M., Paterson, A., Noel, D. R., Al-Tweigeri, T., Tonkin, K., North, S., Azli, N., Riva, A.
(2001). Phase II Study of Docetaxel, Doxorubicin, and Cyclophosphamide as First-Line Chemotherapy for Metastatic Breast Cancer. JCO
19: 314-321
[Abstract][Full Text]
Gennari, A., Salvadori, B., Donati, S., Bengala, C., Orlandini, C., Danesi, R., Del Tacca, M., Bruzzi, P., Conte, P. F.
(1999). Cardiotoxicity of Epirubicin/Paclitaxel-Containing Regimens: Role of Cardiac Risk Factors. JCO
17: 3596-3602
[Abstract][Full Text]
Hensley, M. L., Schuchter, L. M., Lindley, C., Meropol, N. J., Cohen, G. I., Broder, G., Gradishar, W. J., Green, D. M., Langdon, R. J. Jr, Mitchell, R. B., Negrin, R., Szatrowski, T. P., Thigpen, J. T., Von Hoff, D., Wasserman, T. H., Winer, E. P., Pfister, D. G.
(1999). American Society of Clinical Oncology Clinical Practice Guidelines for the Use of Chemotherapy and Radiotherapy Protectants. JCO
17: 3333-3355
[Abstract][Full Text]
Shapiro, C. L., Ervin, T., Welles, L., Azarnia, N., Keating, J., Hayes, D. F.
(1999). Phase II Trial of High-Dose Liposome-Encapsulated Doxorubicin With Granulocyte Colony-Stimulating Factor in Metastatic Breast Cancer. JCO
17: 1435-1435
[Abstract][Full Text]
Singal, P. K., Iliskovic, N.
(1998). Doxorubicin-Induced Cardiomyopathy. NEJM
339: 900-905
[Full Text]
Kowalsky, R. J., Ponto, J. A.
(1989). A Basic Overview of Radiopharmaceuticals and Their Relationship to Nuclear Pharmacy Practice. Journal of Pharmacy Practice
2: 139-147
[Abstract]
Previous
